🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

126 results for “pembrolizumab” Clear

  1. Pembrolizumab Injection

    First Tracks Biotherapeutics

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  2. Phase 1/2 Study of PYX-201 in Combination with Pembrolizumab in Advanced Solid Tumors

    Pyxis Oncology

    Advanced Solid Tumors

    phase 2 other active

    1 trial

  3. The treatment group using pembrolizumab combined with anlotinib and radiotherapy and chemotherapy

    First Tracks Biotherapeutics

    Esophageal Cancer

    phase 2 small molecule active

    1 trial

  4. pembrolizumab

    First Tracks Biotherapeutics

    Advanced Non-squamous Non-small-cell Lung Cancer

    phase 2 small molecule active

    1 trial

  5. pepinemab + pembrolizumab

    VACCINEX, INC.

    Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)

    phase 2 small molecule completed

    1 trial

  6. A Double-Blind, Randomized, Three-arm, Active-Controlled, Parallel-Group, Phase 1 Study Evaluating Pharmacokinetic Similarity of Three Formulations of Pembrolizumab (CT-P51, EU-approved Keytruda, and US-licensed Keytruda) as Adjuvant Therapy in Patients with Completely Resected Stage IIB, IIC, and III Melanoma

    Celltrion Healthcare Hungary Kft.

    Completely Resected Stage IIB, IIC, and III Melanoma

    phase 1 other active

    1 trial

  7. A First-in-Human Study to Evaluate the Safety and Anti-cancer Activity of the product FS120, which is an Antibody medication, to be administered alone or with Pembrolizumab in Subjects with Advanced Malignancies

    Pharma Mar S.A.

    Advanced Malignancies

    phase 1 other active

    1 trial

  8. A Phase 1 First-in-Human Study of the Safety and Effects of VIR-5818 Alone or with Pembrolizumab in Participants with Advanced or Metastatic HER2-Expressing Cancers

    Vir Biotechnology

    Participants with Locally Advanced or Metastatic HER2-Expressing Cancers

    phase 1 other active

    1 trial

  9. A Phase 1 open-label, first-in-human, multi-center, dose escalation and dose expansion study of CLN-619 administered alone or in combination with pembrolizumab in patients with advanced solid tumors.

    Cullinan Therapeutics

    Solid tumors, Non-Small Cell Lung Cancer, Cervical Cancer, Endometrial Cancer, Ovarian Cancer, breast cancer, gastrointestinal cancer

    phase 1 other active

    1 trial

  10. A first-in-human study to learn about how safe BAY 3375968 is, how it moves into, through, and out of the body, and to find its best dose when given alone or with pembrolizumab in participants with advanced solid tumors

    Bayer AG

    Advanced solid tumors

    phase 1 other active

    1 trial

  11. A phase I, open-label, multi-center study of KFA115 as a single agent and in combination with pembrolizumab in patients with select advanced cancers

    Novartis Ophthalmics Europe

    Thymic Carcinoma, Nasopharyngeal Cancer, Anal Cancer, Head and Neck Squamous Cell Carcinoma, Epithelial Ovarian Cancer, Cutaneous melanoma, Mesothelioma, Non-small cell lung cancer, Esophagogastric Cancer, Triple negative breast cancer, Microsatellite Instability High Colorectal Cancer, Clear Cell Renal Cell Carcinoma

    phase 1 other active

    1 trial

  12. A study to learn how safe the study drug BAY 2416964 (AhR inhibitor) in combination with the treatment pembrolizumab is, how this combination affects the body, the maximum amount that can be given, how it moves into, through and out of the body and its action against advanced solid cancers in adults

    Bayer AG

    Advanced solid tumors

    phase 1 other active

    1 trial

  13. A study to test BI 765179 alone and in combination with ezabenlimab in patients with advanced cancer (solid tumors) and BI 765179 in combination with pembrolizumab in patients with advanced head and neck cancer

    Boehringer Ingelheim International GmbH

    Advanced head and neck cancer

    phase 1 other active

    1 trial

  14. A study to test whether treatment with BI 770371 in combination with pembrolizumab with or without cetuximab helps people with head and neck cancer compared with pembrolizumab alone

    Boehringer Ingelheim International GmbH

    Head and neck squamous cell carcinoma

    phase 1 other active

    1 trial

  15. A trial to find out how well CVHNLC works at different dose levels and how safe it is in combination with pembrolizumab in patients with lung cancer that cannot be completely cured.

    CureVac AG

    metastatic squamous non-small cell lung cancer

    phase 1 other active

    1 trial

  16. Comparison between ABP 234 and Keytruda® (Pembrolizumab)

    Amgen Technology (Ireland) UC

    Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

    phase 1 other active

    1 trial

  17. Pembrolizumab

    United Therapeutics Europe Ltd

    Cervix Cancer

    phase 1 other terminated

    1 trial

  18. Pembrolizumab

    Takeda Pharmaceuticals International AG

    Carcinoma, Non-Small-Cell Lung

    phase 1 small molecule completed

    1 trial

  19. Pembrolizumab

    Cardiff Oncology

    Anal Cancer Stage III A

    phase 1 small molecule active

    1 trial

  20. Pembrolizumab

    United Therapeutics Europe Ltd

    Thoracic Tumours

    phase 1 small molecule completed

    1 trial

  21. Pembrolizumab plus autologous dendritic cell vaccine in patients with advanced mesothelioma who have failed prior therapies

    Istituto Gentili S.r.l.

    Mesothelioma

    phase 1 other active

    1 trial

  22. Phase 1 First in Human Study to Explore AMG 355 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

    Amgen Technology (Ireland) UC

    Dose Escalation: Non-small cell lung cancer (NSCLC), colorectal cancer (CRC), gastric cancer (GC), melanoma (MEL). Dose Confirmation: Lead Indication based on data from dose escalation. Dose Expansion: Tertiary Lymphoid Structure positive (TLS+) CRC, GC, and NSCLC.

    phase 1 other active

    1 trial

  23. Phase 1b Study of Dato-DXd in Combination with Pembrolizumab with or without Platinum Chemotherapy in Advanced or Metastatic Non-Small Cell Lung Cancer

    Daiichi Sankyo Europe GmbH

    Non-small cell lung cancer

    phase 1 other active

    1 trial

  24. Study of Abemaciclib with Pembrolizumab in Patients with Stage IV Lung Cancer or Breast Cancer

    Eli Lilly Co.

    Lung Cancer or Breast Cancer

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources